We previously reported that P-retigabine (P-RTG), a retigabine (RTG) analogue bearing a propargyl group at the nitrogen atom in the linker of RTG, displayed moderate anticonvulsant efficacy. Recently, our further efforts led to the discovery of <b>HN37</b> (pynegabine), which demonstrated satisfactory chemical stability upon deleting the ortho liable -NH<sub>2</sub> group and installing two adjacent methyl groups to the carbamate motif. <b>HN37</b> exhibited enhanced activation potency toward neuronal Kv7 channels and high <i>in vivo</i> efficacy in a range of pre-clinical seizure models, including the maximal electroshock test and a 6 Hz model of pharmacoresistant limbic seizures. With its improved chemical stability, strong efficacy, and better safety margin, <b>HN37</b> has progressed to clinical trial in China for epilepsy treatment.